a risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage ii seminoma：一个适应风险的ii期精原细胞瘤放疗或顺铂为基础的化疗策略.pdfVIP

Urologic Oncology: Seminars and Original Investigations 31 (2013) 697–705 Original article A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma a, a a Julien Domont, M.D. *, Christophe Massard, M.D. , Anna Patrikidou, M.D., Ph.D. , c c b Alberto Bossi, M.D., Ph.D. , Renaud de Crevoisier, M.D., Ph.D. , Mathieu Rose, M.C.A. , Pierre Wibault, M.D.c, Karim Fizazi, M.D., Ph.D.a a Department of Medicine, Institut Gustave Roussy, Villejuif, France b Department of Biostatistics, Institut Gustave Roussy, Villejuif, France c Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France Received 14 March 2011; received in revised form 11 April 2011; accepted 13 April 2011 Abstract Objectives: Indications for radiotherapy and chemotherapy in stage II seminoma are currently debated. Materials and methods: Since1980, the policy at Institut Gustave Roussy was to treat patients with stage IIA-B disease with external radiotherapy and patients with stage IIB-C with cisplatin-based chemotherapy. In stage IIB disease, 3 cm was the usual tumor size threshold above which individual patients were considered for chemotherapy. Results: During the period 1980–2001, 67 patients with stage II seminoma were treated: stage IIA (n 5), stage IIB (n 31), and stage IIC